Section Arrow
Quote
IMNM.NASDAQ
- Immunome
Quotes are at least 15-min delayed:2026/04/14 19:25 EDT
After Hours
Last
 23.24
+0.34 (+1.48%)
Bid
22.05
Ask
23.5
High 23.49 
Low 22.9 
Volume 14.60K 
Regular Hours (Closed)
Last
 22.9
+0.28 (+1.24%)
Day High 
23.68 
Prev. Close
22.62 
1-M High
23.14 
Volume 
1.29M 
Bid
22.05
Ask
23.5
Day Low
22.575 
Open
22.76 
1-M Low
19.16 
Market Cap 
2.56B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 21.7 
20-SMA 21.04 
50-SMA 22.07 
52-W High 27.65 
52-W Low 7.15 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.43/-1.81
Enterprise Value
2.56B
Balance Sheet
Book Value Per Share
5.61
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
6.94M
Operating Revenue Per Share
0.06
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HOTHHoth Therapeutics0.6459+0.134+26.18%-- 
After Hours 0.65 +0.0041 +0.63%
ALLOAllogene Therapeutics2.28-0.78-25.49%-- 
After Hours 2.19 -0.09 -3.95%
VRAXVirax Biolabs Group Limited0.148-0.0184-11.06%-- 
After Hours 0.1384 -0.0096 -6.49%
CMNDClearmind Medicine Inc.0.91-0.52-36.36%-- 
After Hours 0.8558 -0.0542 -5.96%
REPLReplimune Group1.95+0.25+14.71%-- 
After Hours 1.9001 -0.0499 -2.56%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.